<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17827" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Arrhythmias</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Desai</surname>
            <given-names>Dhaval S.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hajouli</surname>
            <given-names>Said</given-names>
          </name>
          <aff>Logan Regional Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Dhaval Desai declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Said Hajouli declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>5</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17827.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Arrhythmia entails a broad spectrum of disorders of heart rate and rhythm abnormalities. Arrhythmia is broadly categorized into bradyarrhythmias and tachyarrhythmia based on the heart rate. They are further divided according to the origin, means of transmission, and syndromes associated with it. Patients with an arrhythmia may exhibit a broad spectrum of clinical presentation from being entirely asymptomatic to sudden cardiac arrest. Arrhythmias can be paroxysmal, leading to difficulty in estimating true prevalence. This activity outlines the evaluation and the treatment of various arrhythmias and highlights the role of the interprofessional team in managing patients with these conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the broad categories of arrhythmias</p></list-item><list-item><p>Outline the typical presentation of various arrhythmias.</p></list-item><list-item><p>Identify the typical electrocardiographic features and treatment options for arrhythmias.</p></list-item><list-item><p>Explain the importance of collaboration and communication amongst the interprofessional team to ensure the appropriate selection of candidates for further electrophysiological testing and management option with defibrillators and pacemakers.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17827&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17827">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17827.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Arrhythmia is an abnormal rhythm of the heart. The only normal rhythm of the heart is a normal sinus rhythm. In this rhythm, an impulse is generated in the sinoatrial (SA) node, which is conducted through and slowed down while passing through the&#x000a0;atrioventricular node (AV). It is then conducted through the bundle of His, to the left and right bundle branches, and eventually into the Purkinje fibers. Any deviation from this conduction pathway results in arrhythmia. Arrhythmias can be classified based on various criteria. The most common way to categorize them is based on the rate of conduction as bradyarrhythmia with a heart rate of fewer than 60 beats per minute (bpm) and tachyarrhythmia with a heart rate higher than 100 bpm.</p>
      </sec>
      <sec id="article-17827.s3" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>The prevalence of arrhythmias is expected to be 1.5% to 5% in the general population, with atrial fibrillation being the most common.<xref ref-type="bibr" rid="article-17827.r1">[1]</xref> Arrhythmias may or may not produce any symptoms and can be paroxysmal, leading to difficulty in estimating true prevalence. The overall presence of arrhythmia is associated with higher morbidity and mortality.&#x000a0;</p>
        <p>
<bold>Evaluation of Arrhythmia</bold>
</p>
        <p>In patients suspected of arrhythmias, an electrocardiogram (EKG) is the first step and will usually give the diagnosis. However, at times, the patient may suffer from paroxysmal arrhythmia. The following modalities can be used for diagnosing based on the frequency of the symptoms a patient has secondary to a suspected arrhythmia.</p>
        <list list-type="bullet">
          <list-item>
            <p>Ambulatory EKG monitoring for patients with frequent symptoms</p>
          </list-item>
          <list-item>
            <p>The event recorder needs to be triggered by the patient to record and will not a viable choice for patients with syncope.</p>
          </list-item>
          <list-item>
            <p>Loop event recorder records up to 2 minutes before the trigger. It is good for patients with syncope.</p>
          </list-item>
          <list-item>
            <p>Implantable loop recorder for patients with less frequent symptoms.&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Tachyarrhythmia</bold>
</p>
        <p>Tachyarrhythmia is defined&#x000a0;as an abnormal rhythm with a ventricular heart rate&#x000a0;of 100 beats per minute or more. It<bold>&#x000a0;</bold>can be further classified based on the origin of the arrhythmia into:</p>
        <p>Supraventricular Tachycardia (SVT):&#x000a0;Arrhythmia originating from above the AV node (from atrial origin or AV junction origin).&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Atrial fibrillation (AFib)</p>
          </list-item>
          <list-item>
            <p>Atrial flutter</p>
          </list-item>
          <list-item>
            <p>Atrial tachycardia</p>
          </list-item>
          <list-item>
            <p>Atrial premature complex (PAC)</p>
          </list-item>
          <list-item>
            <p>Atrioventricular nodal reentrant tachycardia (AVNRT)</p>
          </list-item>
          <list-item>
            <p>Atrioventricular reentrant tachycardia (AVRT)</p>
          </list-item>
          <list-item>
            <p>AV junctional extrasystoles</p>
          </list-item>
        </list>
        <p>Ventricular Tachycardia (VT):&#x000a0;The origin of the arrhythmia is below the AV node.</p>
        <list list-type="bullet">
          <list-item>
            <p>Ventricular fibrillation (V-fib)</p>
          </list-item>
          <list-item>
            <p>Ventricular premature beats (PVC)</p>
          </list-item>
          <list-item>
            <p>Ventricular tachycardia (sustained or non-sustained)&#x000a0;</p>
          </list-item>
        </list>
        <p>Tachyarrhythmias can also be classified based on the QRS complex duration into:</p>
        <p>Narrow QRS complex tachycardia when QRS is &#x0003c;120 milliseconds in duration:</p>
        <list list-type="bullet">
          <list-item>
            <p>Sinus tachycardia</p>
          </list-item>
          <list-item>
            <p>Atrial tachycardia (AT)</p>
          </list-item>
          <list-item>
            <p>Atrial flutter</p>
          </list-item>
          <list-item>
            <p>Atrioventricular nodal reentrant tachycardia (AVNRT)</p>
          </list-item>
          <list-item>
            <p>Atrioventricular reentrant tachycardia (AVRT)</p>
          </list-item>
          <list-item>
            <p>Junctional ectopic tachycardia</p>
          </list-item>
          <list-item>
            <p>Sinoatrial nodal reentrant tachycardia (SANRT)</p>
          </list-item>
          <list-item>
            <p>Atrial fibrillation (irregular QRS complexes)</p>
          </list-item>
        </list>
        <p>Wide QRS complex tachycardia (QRS &#x02265;120 milliseconds in duration) is classified as monomorphic ventricular tachycardia, polymorphic ventricular tachycardia, or ventricular fibrillation.</p>
        <p>
<bold>Supraventricular Tachycardia Syndromes</bold>
<xref ref-type="bibr" rid="article-17827.r2">[2]</xref>
<xref ref-type="bibr" rid="article-17827.r3">[3]</xref>
</p>
        <p>These are usually narrow complex tachycardias with QRS width being less than 3 mm or 120 milliseconds on the EKG strip. Supraventricular tachycardia is further classified into atrioventricular reciprocating tachycardia, atrioventricular nodal reentrant tachycardia, and atrial tachycardia based on the mechanism of tachycardia.&#x000a0;</p>
        <p><bold>&#x000a0; &#x000a0; &#x000a0; </bold>I. Atrioventricular reciprocating tachycardia (AVRT): As found in Wolff-Parkinson-White syndrome (the presence of delta wave without arrhythmia doesn&#x02019;t require investigation or treatment).</p>
        <p>Mechanism: Accessory pathway present outside of the AV node-Bundle of Kent. It can be further categorized into:</p>
        <list list-type="bullet">
          <list-item>
            <p>Antidromic:&#x000a0;Conduction down the accessory pathway and up to the AV node leading to the formation of a delta wave.</p>
          </list-item>
          <list-item>
            <p>Orthodromic<italic toggle="yes">:&#x000a0;</italic>Conduction down the AV node into an accessory pathway with no delta wave.</p>
          </list-item>
        </list>
        <p>Signs &#x00026; Symptoms:&#x000a0;Palpitation, shortness of breath, or syncope.</p>
        <p>EKG Findings: Slurred upstroke of the QRS, delta wave, may give an impression of the wide QRS complex.</p>
        <p>Management: Amiodarone or procainamide. If this fails, the next step is synchronized cardioversion.</p>
        <p>Definitive Therapy:&#x000a0;Ablation of the accessory pathway.</p>
        <p>&#x000a0; &#x000a0; &#x000a0; II. Atrioventricular Nodal Reentrant Tachycardia (AVNRT)</p>
        <p>Mechanism: Slow &#x00026; fast fibers present in AV node &#x00026; peri-nodal tissue leading to re-entry.</p>
        <p>Signs &#x00026; Symptoms: Sudden tachycardia, palpitation, shortness of breath, chest tightness, or syncope.</p>
        <p>EKG Findings: Narrow complex tachycardia with P waves hidden in T waves. Heart rate is in the range of 150-160 bpm.</p>
        <p>Management:</p>
        <p>Step 1: Carotid massage/Valsalva maneuver&#x000a0;</p>
        <p>Step 2: Adenosine</p>
        <p>Step 3: Cardioversion</p>
        <p>Step 4: Ablation or chronic suppressive therapy with beta-blockers and calcium channel blockers such as diltiazem/verapamil.</p>
        <p>&#x000a0; &#x000a0; &#x000a0; III.<bold>&#x000a0;</bold>Atrial fibrillation: It is&#x000a0;the most common arrhythmia in the United States. It affects more than 20% of the general population at some time in their lives.<xref ref-type="bibr" rid="article-17827.r4">[4]</xref>&#x000a0;There are five types based on their duration:<xref ref-type="bibr" rid="article-17827.r5">[5]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>New-onset</p>
          </list-item>
          <list-item>
            <p>Paroxysmal: Self-terminating or intermittent</p>
          </list-item>
          <list-item>
            <p>Persistent: Fails to self-terminate within 7 days and requires treatments (medical or electrical cardioversion)&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Long-standing Persistent: Lasts for&#x000a0;&#x02265; 1 year</p>
          </list-item>
          <list-item>
            <p>Permanent: Persistent for &#x02265; 1 year despite treatment</p>
          </list-item>
        </list>
        <p>Mechanism: Multiple reentrant wavelets due to atrial ectopy from muscle fibers near the proximal part of the pulmonary vein.</p>
        <p>Signs &#x00026; Symptoms: It can be asymptomatic&#x000a0;or can cause symptoms like palpitation, shortness of breath, irregularly irregular pulse, or even hypotension.</p>
        <p>EKG Findings:&#x000a0;Irregularly irregular narrow complex tachycardia with no discernable P-waves.</p>
        <p>Management: The management&#x000a0;strategy for atrial fibrillation can be classified into rate control or rhythm control. The decision to use a rate control or a rhythm-control strategy depends on the hemodynamic stability, candidacy for ablation, and the presence of co-morbidities. Patients with atrial fibrillation are at increased risk of ischemic-embolic stroke, and anticoagulation recommendations are based on the CHA2DS2VaSc score.</p>
        <p>The CHA2DS2VaSc score&#x000a0;is determined by the presence of the following factors: Congestive heart failure (CHF) with ejection fraction (EF) less than 40%, hypertension, age &#x0003e; 65 years, diabetes mellitus, history of stroke (non-hemorrhagic), or transient ischemic attack (TIA), vascular disease (peripheral vascular disease - PVD), age &#x0003e; 75 years, female sex. Each factor adds a point to the score, except for a history of stroke/TIA, which adds 2 points.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>If the score is 0: No anticoagulation or aspirin based on individual assessment</p>
          </list-item>
          <list-item>
            <p>If the score is 1: Aspirin or anticoagulation based on individual assessment.</p>
          </list-item>
          <list-item>
            <p>If the score is 2 or more: Anticoagulation is recommended if not at high risk of bleeding.&#x000a0;</p>
          </list-item>
        </list>
        <p>Rate Control Strategy<bold>:</bold>&#x000a0;The heart rate goal is &#x0003c; 110 bpm in patients with chronic atrial fibrillation. It can be achieved with either beta-blockers or calcium channel blockers. Digoxin is usually used as adjuvant therapy in a patient with a "difficult to control" heart rate or in heart failure patients.</p>
        <p>Cardioversion Strategy:<bold>&#x000a0;</bold>Cardioversion is preferred in hemodynamically unstable patients or if rate control fails. It is also preferred in a young patient with no other co-morbidities. Cardioversion can be performed within 36 hrs of the onset of atrial fibrillation, but if the presentation is delayed or is of unknown duration, the absence of thrombi needs to be confirmed with a transesophageal echocardiogram (TEE). If a thrombus is present on an echocardiogram, the patient will need anticoagulation for at least three weeks before cardioversion can be performed. The patient needs to be on anticoagulation for at least four weeks post cardioversion. Various modalities are available for cardioversion therapy and include synchronized electric cardioversion or chemical cardioversion with medications including flecainide, propafenone, amiodarone, or dronedarone. Maze procedure is usually reserved for the patient undergoing other cardiac surgery.</p>
        <list list-type="bullet">
          <list-item>
            <p>Atrial Flutter<xref ref-type="bibr" rid="article-17827.r6">[6]</xref></p>
          </list-item>
        </list>
        <p>Mechanism: Reentrant circuit usually around the tricuspid annulus in the right atrium.</p>
        <p>Signs &#x00026; Symptoms: Can be asymptomatic, or it can cause palpitation, shortness of breath, or hypotension.</p>
        <p>EKG Findings: Regular tachycardia with Saw-tooth appearance of P wave with a variable degree of AV block.</p>
        <p>Management: General goals include control of ventricular rate with AV blocking agents (beta-blockers or calcium channel blockers), but the restoration of sinus rhythm through cardioversion or ablation is preferred.&#x000a0;&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>&#x000a0;Multifocal Atrial Tachycardia (MAT)</p>
          </list-item>
        </list>
        <p>Mechanism: multiple automatic atrial foci due to increased sympathetic tone secondary to various causes, including hypoxemia (chronic obstructive pulmonary disease (COPD), or stimulant use.</p>
        <p>Signs &#x00026; Symptoms: Usually asymptomatic. Patients will have symptoms of the underlying illness, such as dyspnea.</p>
        <p>EKG Findings: Three or more P wave morphologies with different PR intervals.</p>
        <p>Management: Oxygen therapy if hypoxemic and treatment of the underlying cause.</p>
        <p>Refractory cases: Rate Control with calcium channel blockers as the first choice in the setting of COPD followed by beta-blockers.</p>
        <list list-type="bullet">
          <list-item>
            <p>Junctional tachycardia:<xref ref-type="bibr" rid="article-17827.r7">[7]</xref>&#x000a0;Arrhythmia originating from or near the AV node.</p>
          </list-item>
        </list>
        <p>Mechanism: Rhythm arising from the AV node.</p>
        <p>Risk Factors:&#x000a0;Post cardiac surgery, myocardial ischemia (or during reperfusion), or&#x000a0;digoxin toxicity.</p>
        <p>Signs &#x00026; Symptoms:&#x000a0;Usually well-tolerated and asymptomatic.</p>
        <p>EKG Findings:&#x000a0;Inverted P Wave in the lead 2 with short PR or No P waves with a narrow complex.</p>
        <p>Management: Treat the underlying cause.&#x000a0;</p>
        <p><bold>&#x000a0; &#x000a0; &#x000a0;</bold>IV.<bold> Ventricular Tachycardia:&#x000a0;</bold>Origin is below the AV node.&#x000a0;It is the major cause of sudden cardiac deaths in the United States.</p>
        <p>a) Non-Sustained Ventricular Tachycardia:<xref ref-type="bibr" rid="article-17827.r8">[8]</xref><bold>&#x000a0;</bold>When the rapid ventricular rhythm terminates on its own within 30 seconds.</p>
        <p>Mechanism: Channelopathies secondary to structural abnormality, electrolyte disturbances, metabolic imbalance, and the effect of pro-arrhythmic drugs.</p>
        <p>Risk Factors: Structural or ischemic heart disease.</p>
        <p>Signs &#x00026; Symptoms: Asymptomatic or palpitations.</p>
        <p>EKG Findings: Monomorphic wide complex with more than three beats in a row but lasts less than three seconds.</p>
        <p>Management: Implantable cardioverter-defibrillator (ICD) and/or medical therapy.</p>
        <p>b) Sustained Ventricular Tachycardia</p>
        <p>Mechanism: Presence of damaged fibers in ischemic heart disease leading to re-entry of current. Some patients do not have structural heart disease. Approximately 10% of the cases are idiopathic.</p>
        <p>Risk Factors:&#x000a0;Structural heart disease and post-myocardial infarction.</p>
        <p>Signs &#x00026; Symptoms: Palpitation, hypotension, or syncope.</p>
        <p>EKG Findings:&#x000a0;Monomorphic wide complex tachycardia.</p>
        <p>Management: Intravenous lidocaine, amiodarone, or procainamide. Catheter ablation is an option too.</p>
        <p>c) Ventricular Fibrillation</p>
        <p>Mechanism: Presence of damaged fibers in ischemic heart disease leading to re-entry of current leading to disorganized high-frequency excitation. Patients with Cardiomyopathies can have Ventricular fibrillation due to an increase in end-diastolic pressure, wall tension, or the presence of abnormal channels in ventricular fibers.</p>
        <p>Risk Factors:&#x000a0;Structural heart disease and post-myocardial infarction.</p>
        <p>Signs &#x00026; Symptoms:&#x000a0;Syncope and death if not treated immediately.</p>
        <p>EKG Findings:&#x000a0;Polymorphic fibrillatory waves.</p>
        <p>Management:&#x000a0;Unsynchronized cardioversion followed by amiodarone.</p>
        <p>d) Torsades De Pointes:</p>
        <p>Mechanism: It is usually precipitated by premature ventricular contraction leading to the &#x0201c;R on T phenomenon.&#x0201d;</p>
        <p>Risk Factors:&#x000a0;Congenital long QTc with hypokalemia&#x000a0;and hypomagnesemia.</p>
        <p>Signs &#x00026; Symptoms:&#x000a0;Syncope and death if not treated immediately.</p>
        <p>EKG Findings:&#x000a0;Polymorphic wide-complex tachycardia with a heart rate &#x0003e; 300 bpm.</p>
        <p>Management: Intravenous magnesium or Isoproterenol, which increases heart rate and decreases QT-duration. Avoid hypokalemia and hypomagnesemia. Chronic therapy with beta-blockers in patients with long QT syndrome.</p>
        <p><bold>Bradyarrhythmias:</bold><xref ref-type="bibr" rid="article-17827.r9">[9]</xref><xref ref-type="bibr" rid="article-17827.r10">[10]</xref>&#x000a0;Bradyarrhythmia is defined as a heart rate below 60 beats per minute (bpm) and comprises several rhythm disorders, including atrioventricular (A-V) blocks and sinus node disorders.</p>
        <p>Sinus Bradycardia</p>
        <p>Mechanism:&#x000a0;Increased vagal tone. It can be physiological in athletes.</p>
        <p>Signs &#x00026; Symptoms: Usually asymptomatic. It can lead to orthostasis or dizziness if pathological.</p>
        <p>EKG Findings: Sinus rhythm with an upright P wave in lead II and biphasic in V1.</p>
        <p>Management: No treatment is required unless pathological with an inadequate heart rate increase with leg raise test. Treat with isoproterenol or pacemaker if no relief.&#x000a0;</p>
        <p>Atrioventricular Blocks</p>
        <p>Mechanism:&#x000a0;Atrial impulses are conducted with a delay or not at all when an electrical impulse reaches a tissue that not excitable or is in a refractory period.</p>
        <p>a) First Degree AV Block:&#x000a0;Caused by increased vagal tone or conduction impairment or due to medications.</p>
        <p>Signs &#x00026; Symptoms: Generally asymptomatic but can cause dizziness.</p>
        <p>EKG Findings: PR interval is greater than 200 milliseconds.</p>
        <p>Management: Usually, no need to treat.</p>
        <p>&#x000a0;b) Second Degree AV Block:&#x000a0;Further classified into Mobitz I block, where there is a progressive prolongation of the PR interval followed by a skipped beat, and Mobitz II block, where there is a randomly dropped QRS complex on an EKG.</p>
        <p>Sign &#x00026; Symptoms: Can be asymptomatic, dizziness, palpitations, weakness, syncope.</p>
        <p>EKG Findings:&#x000a0;Mobitz type I shows progressive prolongation of the PR interval followed by a dropped QRS complex or dropped beat. Mobitz type II has randomly dropped QRS complexes.</p>
        <p>Management: Pacemaker is indicated in symptomatic Mobitz I and all of Mobitz II heart block.</p>
        <p>&#x000a0;c) Third Degree or complete AV Block</p>
        <p>Mechanism: Lack of conduction of atrial impulse to ventricle leading to independent contractions.</p>
        <p>Sign &#x00026; Symptoms: Profound bradycardia, hypotension, and can lead to asystole and cardiac arrest.</p>
        <p>EKG Findings: Bradycardia, P waves occur independently of QRS and Wide QRS for ventricular rhythm.</p>
        <p>Management: Pacemaker placement.</p>
        <p>
<bold>Sinus Node Dysfunction</bold>
</p>
        <p>Mechanism: Senescence of the SA node, an ischemic event involving the SA node leading to impulse generation at a slower rate.</p>
        <p>a) Sinus Pause: When the SA node has delayed impulse generation.</p>
        <p>b) Sinus Arrest: Failure of impulse generation.</p>
        <p>c) SA Nodal Exit Block: Failure of impulse transmission.</p>
        <p>Sign &#x00026; Symptoms:&#x000a0;Bradycardia, dizziness, palpitation, or syncope.</p>
        <p>EKG Findings: P wave not originating at a determined rate with regularity</p>
        <p>Management: Symptomatic patients require pacemaker placement.</p>
      </sec>
      <sec id="article-17827.s4" sec-type="Other Issues">
        <title>Other Issues</title>
        <p>
<bold>Hypertrophic Obstructive Cardiomyopathy</bold>
</p>
        <p>Mechanism: Subaortic outflow tract obstruction from abnormal hypertrophy of the septal region of the heart, leading to precipitation of ventricular arrhythmias.</p>
        <p>Risk Factor: Autosomal dominant mutation in the gene coding for cardiac sarcomere(Beta myosin heavy chain). Suspect this in a patient with a family history of sudden cardiac death in 2 first-degree relatives.</p>
        <p>Symptoms: Syncope with exertion, palpitation, develops early heart failure symptoms.&#x000a0;</p>
        <p>Treatment: Beta-blockers are the mainstay of therapy. Surgery is indicated for patients with obstructive physiology with an outflow gradient greater than 50 mmHg. The defibrillator is indicated for patients who are symptomatic post maximal medical therapy, abnormal systolic blood pressure response to exercise, septal thickness &#x0003e; 30 mm, runs of ventricular tachycardia, or ventricular fibrillation on telemetry or during the stress test.</p>
        <p>Indications for ICD placements to prevent sudden cardiac death with arrhythmia:</p>
        <list list-type="bullet">
          <list-item>
            <p>CHF with&#x000a0;EF &#x0003c; 35%&#x000a0;after three months of maximal medical therapy.</p>
          </list-item>
          <list-item>
            <p>Myocardial infarction (MI) with&#x000a0;EF &#x0003c; 40%&#x000a0;with inducible VT or VF in electrophysiological studies.</p>
          </list-item>
          <list-item>
            <p>MI with&#x000a0;EF &#x0003c; 30%</p>
          </list-item>
          <list-item>
            <p>Patients with long QT&#x000a0;if&#x000a0;QTc &#x0003e; 500 and an episode of unexplained syncope or Holter showing NSVTs</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17827.s5" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Arrhythmias can pose a diagnostic dilemma. The patient presentation can be varied even for the same arrhythmia and can require a different management approach based on the patient's clinical condition and characteristics. While clinical history, physical exam, and EKG findings may reveal particular kinds of arrhythmia, it can sometimes be challenging to form an appropriate management plan without an expert opinion. While an internist is always involved in the care of patients with arrhythmia, it is essential to consult an interprofessional team of specialists, including cardiologists, electrophysiologists, and interventionists.</p>
        <p>Based on the condition, the patient may need further evaluation with electrophysiological or ischemia workup for the cause of arrhythmia, which will eventually be treated by a cardiac catheterization or ablation procedure. The nurses are vital members of the interprofessional group as they will monitor the patient's vital signs, telemetry, and assist with the patient and family's education. It has been shown that hospitals with a dedicated arrhythmia team consisting of a nurse, electrophysiologist, noninvasive arrhythmia expert, and internist have shown significant improvement in the outcomes of patients.<xref ref-type="bibr" rid="article-17827.r11">[11]</xref></p>
      </sec>
      <sec id="article-17827.s6">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17827&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17827">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17827/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17827">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-17827.s7">
        <fig id="article-17827.image.f1" position="float" orientation="portrait">
          <caption>
            <p>A graphical representation of the Electrical conduction system of the heart showing the Sinoatrial node, Atrioventricular node, Bundle of His, Purkinje fibers, and Bachmann's bundle Contributed by Wikimedia Commons (Public Domain)</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ConductionsystemoftheheartwithouttheHeart-en.svg" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-17827.s8">
        <title>References</title>
        <ref id="article-17827.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lakshminarayan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Herzog</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Qureshi</surname>
                <given-names>AI</given-names>
              </name>
            </person-group>
            <article-title>Clinical epidemiology of atrial fibrillation and related cerebrovascular events in the United States.</article-title>
            <source>Neurologist</source>
            <year>2008</year>
            <month>May</month>
            <volume>14</volume>
            <issue>3</issue>
            <fpage>143</fpage>
            <page-range>143-50</page-range>
            <pub-id pub-id-type="pmid">18469671</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17827.r2">
          <label>2</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Kaplan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lala</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <chapter-title>Paroxysmal Atrial Tachycardia</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>26</day>
            <pub-id pub-id-type="pmid">30855901</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17827.r3">
          <label>3</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Hafeez</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Quintanilla Rodriguez</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Grossman</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <chapter-title>Paroxysmal Supraventricular Tachycardia</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>2</month>
            <day>5</day>
            <pub-id pub-id-type="pmid">29939521</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17827.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heeringa</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>van der Kuip</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Hofman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kors</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>van Herpen</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Stricker</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Stijnen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lip</surname>
                <given-names>GY</given-names>
              </name>
              <name>
                <surname>Witteman</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study.</article-title>
            <source>Eur Heart J</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>27</volume>
            <issue>8</issue>
            <fpage>949</fpage>
            <page-range>949-53</page-range>
            <pub-id pub-id-type="pmid">16527828</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17827.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schmidt</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kisselbach</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schweizer</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Katus</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>The pathology and treatment of cardiac arrhythmias: focus on atrial fibrillation.</article-title>
            <source>Vasc Health Risk Manag</source>
            <year>2011</year>
            <volume>7</volume>
            <fpage>193</fpage>
            <page-range>193-202</page-range>
            <pub-id pub-id-type="pmid">21490945</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17827.r6">
          <label>6</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Rodriguez Ziccardi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Goyal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Maani</surname>
                <given-names>CV</given-names>
              </name>
            </person-group>
            <chapter-title>Atrial Flutter</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2022</year>
            <month>12</month>
            <day>8</day>
            <pub-id pub-id-type="pmid">31082029</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17827.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cundiff</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Cannon</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Snyder</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Atrioventricular junctional tachycardia with exit block in an adolescent.</article-title>
            <source>HeartRhythm Case Rep</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>4</volume>
            <issue>12</issue>
            <fpage>594</fpage>
            <page-range>594-597</page-range>
            <pub-id pub-id-type="pmid">30581740</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17827.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Allen</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Abrich</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Bibby</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Fishman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Sorajja</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Prevalence and Prognostic Significance of Nonsustained Ventricular Tachycardia in Patients With a Left Ventricular Ejection Fraction from 35% to 50.</article-title>
            <source>Am J Cardiol</source>
            <year>2018</year>
            <month>Feb</month>
            <day>01</day>
            <volume>121</volume>
            <issue>3</issue>
            <fpage>330</fpage>
            <page-range>330-335</page-range>
            <pub-id pub-id-type="pmid">29224709</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17827.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kerola</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Eranti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aro</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Haukilahti</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Holkeri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Junttila</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Kentt&#x000e4;</surname>
                <given-names>TV</given-names>
              </name>
              <name>
                <surname>Rissanen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Vittinghoff</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Knekt</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Heli&#x000f6;vaara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Huikuri</surname>
                <given-names>HV</given-names>
              </name>
              <name>
                <surname>Marcus</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Risk Factors Associated With Atrioventricular Block.</article-title>
            <source>JAMA Netw Open</source>
            <year>2019</year>
            <month>May</month>
            <day>03</day>
            <volume>2</volume>
            <issue>5</issue>
            <fpage>e194176</fpage>
            <pub-id pub-id-type="pmid">31125096</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17827.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leonelli</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>De Ponti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bagliani</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Challenges in Bradicardias Interpretation.</article-title>
            <source>Card Electrophysiol Clin</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>261</fpage>
            <page-range>261-281</page-range>
            <pub-id pub-id-type="pmid">31084850</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17827.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stewart</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ball</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Horowitz</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Marwick</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Mahadevan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Abhayaratna</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>YK</given-names>
              </name>
              <name>
                <surname>Esterman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Scuffham</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Carrington</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Standard versus atrial fibrillation-specific management strategy (SAFETY) to reduce recurrent admission and prolong survival: pragmatic, multicentre, randomised controlled trial.</article-title>
            <source>Lancet</source>
            <year>2015</year>
            <month>Feb</month>
            <day>28</day>
            <volume>385</volume>
            <issue>9970</issue>
            <fpage>775</fpage>
            <page-range>775-84</page-range>
            <pub-id pub-id-type="pmid">25467562</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
